Study shows benefits with Cefaly for Migraine-STX-Med

A study to determine whether transcutaneous supraorbital nerve stimulation (tSNS) with the Cefaly device, from STX-Med, for episodic Migraine prevention, is safe and effictive in larger cohorts of headache sufferers has been published. The study assessed the satisfaction with the Cefaly device in 2,313 headache sufferers who rented the device for a 40-day trial period via Internet. After 58.2 days on average, 46.6% of the patients were not satisfied and returned the device, but compliance checks showed that they used it only for 48.6% of the recommended time. The remaining 54.4% of subjects were satisfied with the tSNS treatment and willing to purchase the device.

Ninety-nine subjects out of the 2,313 (4.3%) reported one or more AEs, but none of them was serious. The most frequent AEs were local pain/intolerance to paresthesia (47 subjects, i.e. 2.03%), arousal changes (mostly sleepiness/fatigue i.e. 0.82%), headache after the stimulation (0.52%). A transient local skin allergy was seen in 2 subjects. Results were published in The Journal of Headache and Pain: "Safety and patients� satisfaction of transcutaneous Supraorbital NeuroStimulation (tSNS) with the Cefaly device in headache treatment: a survey of 2,313 headache sufferers in the general population." Delphine Magis et al. The Journal of Headache and Pain, December 2013, 14:95 http://link.springer.com/article/10.1186%2F1129-2377-14-95